Fortress Biotech (FBIO) Competitors

Codexis (NASDAQ:CDXS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.

Do analysts recommend CDXS or FBIO?

Codexis currently has a consensus target price of $8.33, suggesting a potential upside of 230.69%. Fortress Biotech has a consensus target price of $21.00, suggesting a potential upside of 1,047.54%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, CDXS or FBIO?

Codexis has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Do insiders & institutionals believe in CDXS or FBIO?

78.5% of Codexis shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 2.1% of Codexis shares are held by insiders. Comparatively, 33.4% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Does the media refer more to CDXS or FBIO?

In the previous week, Codexis had 7 more articles in the media than Fortress Biotech. MarketBeat recorded 7 mentions for Codexis and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.87 beat Codexis' score of 1.09 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Positive
Fortress Biotech	Very Positive

Which has stronger earnings & valuation, CDXS or FBIO?

Fortress Biotech has lower revenue, but higher earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$59.35M	3.52	-$76.24M	-$0.90	-2.80
Fortress Biotech	$57.68M	0.94	-$60.64M	-$2.78	-0.66

Is CDXS or FBIO more profitable?

Fortress Biotech has a net margin of -84.53% compared to Codexis' net margin of -96.35%. Fortress Biotech's return on equity of 0.00% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-96.35%	-71.56%	-38.00%
Fortress Biotech	-84.53%	N/A	-34.93%

Does the MarketBeat Community believe in CDXS or FBIO?

Codexis received 23 more outperform votes than Fortress Biotech when rated by MarketBeat users. However, 63.69% of users gave Fortress Biotech an outperform vote while only 61.47% of users gave Codexis an outperform vote.

Company	Underperform	Outperform
Codexis	Outperform Votes 351 61.47%	Underperform Votes 220 38.53%
Fortress Biotech	Outperform Votes 328 63.69%	Underperform Votes 187 36.31%

Summary

Fortress Biotech beats Codexis on 12 of the 18 factors compared between the two stocks.